Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib with Rituximab and Vincristine in Aggressive B-Cell Lymphoma
NCT01397825Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2011
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of alisertib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, transformed (t-FL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), sponsored by Millennium Pharmaceuticals. Started Aug 2011; status: completed.
02
Drugs
alisertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma, transformed (t-FL)mantle cell lymphoma (MCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT01397825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397825.